emirates7 - Scientists have developed a smarter way to activate the immune system against cancer, potentially making treatments safer and more precise.
The research focuses on a powerful pathway inside our cells known as STING. When triggered, STING acts like an internal alarm system, sending out signals that summon the body's immune system to attack.
Drugs that activate this pathway have shown promise in cancer therapy, but until now, they faced a major problem: if switched on in healthy tissues, they can cause harmful and sometimes dangerous side effects.
To solve this problem, researchers from the University of Cambridge designed a two-part 'prodrug' system, made of two harmless components that only activate when they meet in a tumour.
One component of the drug was 'caged' so that it remains inactive until it encounters a tumour-specific enzyme called β-glucuronidase, which is rarely found in healthy tissue. When the caged component meets this enzyme inside a tumour, it is unlocked and reacts with the second component.
Together, the two pieces form a powerful STING activator, switching on the immune system only where the cancer is located. The molecules are designed to recognise and stick to each other efficiently, so the reaction happens quickly and selectively inside tumours.
"This is like sending two safe packages into the body that only unlock and combine when they meet the tumour's unique chemistry," said Professor Gonçalo Bernardes from Cambridge's Yusuf Hamied Department of Chemistry, who led the research. “The result is a strong immune-activating drug that appears only where it is needed.”
Laboratory experiments showed that the two drug components have almost no activity on their own. But when they met in tumour conditions, the active compound formed and successfully triggered STING at very low concentrations. In zebrafish and mouse models engineered to produce β-glucuronidase, the drug became active almost exclusively in the tumours, sparing vital organs such as the liver, kidney, and heart. Their results are reported in the journal Nature Chemistry.
This level of precision represents a major advance for STING-based therapies, which have previously struggled to distinguish between healthy and cancerous tissues. By using a simple chemical design, the Cambridge team achieved targeted activation of the immune system without relying on complex or artificial reactions.
Beyond cancer, the researchers believe this method could inspire a new class of precision medicines.
The research focuses on a powerful pathway inside our cells known as STING. When triggered, STING acts like an internal alarm system, sending out signals that summon the body's immune system to attack.
Drugs that activate this pathway have shown promise in cancer therapy, but until now, they faced a major problem: if switched on in healthy tissues, they can cause harmful and sometimes dangerous side effects.
To solve this problem, researchers from the University of Cambridge designed a two-part 'prodrug' system, made of two harmless components that only activate when they meet in a tumour.
One component of the drug was 'caged' so that it remains inactive until it encounters a tumour-specific enzyme called β-glucuronidase, which is rarely found in healthy tissue. When the caged component meets this enzyme inside a tumour, it is unlocked and reacts with the second component.
Together, the two pieces form a powerful STING activator, switching on the immune system only where the cancer is located. The molecules are designed to recognise and stick to each other efficiently, so the reaction happens quickly and selectively inside tumours.
"This is like sending two safe packages into the body that only unlock and combine when they meet the tumour's unique chemistry," said Professor Gonçalo Bernardes from Cambridge's Yusuf Hamied Department of Chemistry, who led the research. “The result is a strong immune-activating drug that appears only where it is needed.”
Laboratory experiments showed that the two drug components have almost no activity on their own. But when they met in tumour conditions, the active compound formed and successfully triggered STING at very low concentrations. In zebrafish and mouse models engineered to produce β-glucuronidase, the drug became active almost exclusively in the tumours, sparing vital organs such as the liver, kidney, and heart. Their results are reported in the journal Nature Chemistry.
This level of precision represents a major advance for STING-based therapies, which have previously struggled to distinguish between healthy and cancerous tissues. By using a simple chemical design, the Cambridge team achieved targeted activation of the immune system without relying on complex or artificial reactions.
Beyond cancer, the researchers believe this method could inspire a new class of precision medicines.